Login to Your Account

Bid in NAION could open door to Regenera trial in stroke

By Randy Osborne
Staff Writer

Monday, September 25, 2017

Regenera Pharma Ltd. CEO Jordan Rubinson told BioWorld that “there’s over $1 billion dollars of market value, of revenues, in the first five years” if the company can succeed in a planned phase III trial and win approval for RPH-201 in NAION, “essentially a stroke of the optic nerve.”

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription